Tumor-infiltrating lymphocytes contain a higher proportion of FOXP3+ T lymphocytes in cervical cancer

Journal of the Formosan Medical Association

Volumn 110, Issue 9, 2011, Pages 580-586

  Wu, Ming Yih ^a   Kuo, Tzu Yun ^b   Ho, Hong Nerng ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasm; FOXP3; Treg cells

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER TISSUE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPATHOGENESIS; LYMPH NODE METASTASIS; PHENOTYPE; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MICROSCOPY, CONFOCAL; T-LYMPHOCYTES, REGULATORY; UTERINE CERVICAL NEOPLASMS;

EID: 81155162530     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2011.07.005     Document Type: Article

References (29)

1. Ziegler S.F. FOXP3: of mice and men. Annu Rev Immunol 2006, 24:209-226.
2. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
3. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
4. Khattri R., Cox T., Yasayko S.A., Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4:337-342.
5. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307.
6. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-4772.
7. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-2761.
8. Ichihara F., Kono K., Takahashi A., Kawaida H., Sugai H., Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003, 9:4404-4408.
9. Ormandy L.A., Hillemann T., Wedemeyer H., Manns M.P., Greten T.F., Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005, 65:2457-2464.
10. Kobayashi A., Greenblatt R.M., Anastos K., Minkoff H., Massad L.S., Young M., et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004, 64:6766-6774.
11. Bell M.C., Edwards R.P., Partridge E.E., Kuykendall K., Conner W., Gore H., et al. CD8+ T lymphocytes are recruited to neoplastic cervix. J Clin Immunol 1995, 15:130-136.
12. Sheu B.C., Chiou S.H., Lin H.H., Chow S.N., Huang S.C., Ho H.N., et al. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. Cancer Res 2005, 65:2921-2929.
13. Grossman W.J., Verbsky J.W., Barchet W., Colonna M., Atkinson J.P., Ley T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004, 21:589-601.
14. Roncador G., Brown P.J., Maestre L., Hue S., Martinez-Torrecuadrada J.L., Ling K.L., et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005, 35:1681-1691.
15. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
16. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
17. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999, 163:5211-5218.
18. Steitz J., Bruck J., Lenz J., Knop J., Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001, 61:8643-8646.
19. Loddenkemper C., Hoffmann C., Stanke J., Nagorsen D., Baron U., Olek S., et al. Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer. Cancer Sci 2009, 100:1112-1117.
20. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
21. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005, 202:919-929.
22. Tarbell K.V., Yamazaki S., Olson K., Toy P., Steinman R.M. CD25+CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004, 199:1467-1477.
23. Yamazaki S., Iyoda T., Tarbell K., Olson K., Velinzon K., Inaba K., et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003, 198:235-247.
24. Sheu B.C., Lin R.H., Lien H.C., Ho H.N., Hsu S.M., Huang S.C. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 2001, 167:2972-2978.
25. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
26. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
27. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999, 20:46-52.
28. Bennett M.W., O'Connell J., O'Sullivan G.C., Brady C., Roche D., Collins J.K., et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998, 160:5669-5675.
29. Shibakita M., Tachibana M., Dhar D.K., Kotoh T., Kinugasa S., Kubota H., et al. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 1999, 5:2464-2469.